儿童流感疫苗接种预防流感及流感样疾病的真实世界有效性
基于意大利儿科初级保健数据库的人群队列研究,纳入2022-2023和2023-2024季节2-14岁儿童,比较四价减毒活流感疫苗(LAIV-4)与灭活流感疫苗(IIV)相对于未接种儿童预防流感/流感样疾病的有效性。LAIV-4总体有效性43%(95%CI 32%-53%),IIV为54%(95%CI 46%-61%);2023-2024季节LAIV-4有效性略低于IIV(p=0.048)。结论为两者总体有效性中等且相当。
要点
- LAIV-4总体有效性43%(95%CI 32%-53%),IIV为54%(95%CI 46%-61%)。
- 2022-2023季节LAIV-4有效性38%(95%CI 12%-56%),IIV为49%(95%CI 37%-58%)。
- 2023-2024季节LAIV-4有效性40%(95%CI 25%-52%),低于IIV的58%(95%CI 44%-68%)(p=0.048)。
核心结论
- 在意大利儿童中观察到LAIV-4与IIV预防流感/流感样疾病的总体有效性中等且相当。
研究设计与样本
- 基于Pedianet儿科初级保健数据库的人群队列研究,纳入2022年9月至2024年4月2-14岁儿童。
- 2022-2023季节纳入65,545名儿童(472,173人月),2023-2024季节纳入72,377名儿童(527,348人月)。
- 接种LAIV-4或IIV的儿童与未接种儿童比较,主要结局为首次流感或流感样疾病发作。
- 采用调整混合效应Cox模型估计风险比(HR)及疫苗有效性(VE)的95%置信区间(CI)。
主要发现
- 2022-2023和2023-2024季节疫苗接种率分别为12.71和12.85/1000人月。
- 与未接种儿童相比,LAIV-4总体有效性为43%(95%CI 32%-53%),IIV为54%(95%CI 46%-61%)。
- 2022-2023季节LAIV-4有效性38%(95%CI 12%-56%),IIV为49%(95%CI 37%-58%)。
- 2023-2024季节LAIV-4有效性40%(95%CI 25%-52%),低于IIV的58%(95%CI 44%-68%)(p=0.048)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Quadrivalent live attenuated influenza vaccines (LAIV-4) offer an alternative to inactivated influenza vaccines (IIV) for children aged 2-17 years, but data on their comparative effectiveness are limited. This study assessed vaccination rates and real-world effectiveness of LAIV-4 and IIV in preventing influenza and influenza-like illness (ILI) in Italian children during the 2022-2023 and 2023-2024 seasons. METHODS: We conducted a population-based cohort study of children aged 2-14 years from September 2022 to April 2024, using data from Pedianet, a pediatric primary care database of anonymized records from family pediatricians. Children vaccinated with LAIV-4 or IIV were compared to unvaccinated children. The primary outcome was any first influenza or ILI episode. Monthly vaccination incidence rates per 1000 person-months were calculated for each vaccine type. Hazard ratios (HRs) and their 95 % confidence intervals (CIs) for vaccine effectiveness (VE) were estimated using adjusted mixed-effects Cox models. RESULTS: A total of 65,545 (472,173 person-months) and 72,377 (527,348 person-months) children were included for the 2022-2023 and 2023-2024 seasons, respectively. Vaccination rates were 12.71 and 12.85 per 1000 person-months, respectively. Compared to unvaccinated children, LAIV-4 had an overall effectiveness of 43 % (95 % CI, 32 %-53 %), while IIV effectiveness was 54 % (95 % CI, 46 %-61 %). In 2022-2023, LAIV-4 (38 % [95 % CI, 12 %-56 %]) and IIV (49 % [95 % CI, 37 %-58 %]) had comparable effectiveness. In 2023-2024, LAIV-4 (40 % [95 % CI, 25 %-52 %]) was slightly less effective than IIV (58 % [95 % CI, 44 %-68 %])(p = 0.048). CONCLUSIONS: An overall moderate, comparable effectiveness of LAIV-4 and IIV in preventing influenza/ILI among Italian children was observed.
引用
- Rigamonti V, Torri V, Morris SK, et al. Real-world effectiveness of influenza vaccination in preventing influenza and influenza-like illness in children. Vaccine. 2025. PMID: 40023131. doi:10.1016/j.vaccine.2025.126946
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。